A Proof of Concept Trial of a Sirtuin-NAD Activator in Alzheimer's Disease
Latest Information Update: 09 Jun 2025
At a glance
- Drugs MIB-626 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Biomarker; Pharmacokinetics; Proof of concept
Most Recent Events
- 03 Jun 2025 Planned End Date changed from 1 Dec 2025 to 31 Dec 2025.
- 03 Jun 2025 Planned primary completion date changed from 30 Sep 2025 to 31 Oct 2025.
- 10 Mar 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.